Objective. Rare cancers have been traditionally understudied, reducing the progress of research and hindering decisions for patients, physicians, and policy makers. We evaluated the descriptive epidemiology of rare cancers using a large, representative, population-based dataset from cancer registries in the United States.
Rare health conditions typically receive far less scientific attention and fiscal support than their more common counterparts. This utilitarian approach has impeded the understanding of even the basic descriptive epidemiology of rare cancers.
1,2 Knowledge of rare cancers is often derived from case reports, single-institution case series, or, at best, smaller multicenter series. [3] [4] [5] Conclusions drawn from such selected studies may be misleading, as they do not necessarily reflect the characteristics of the underlying population of all similar cancers. 6 Many rare cancers can be highly fatal, and yet patients and caregivers have a limited evidence base to guide clinical deliberations. Enhanced research on rare cancers can facilitate improvements in diagnosis, treatment, and patient outcomes, 7 and can also lead to important discoveries about underlying mechanisms of tumor development. 8 In an effort to promote and synergize epidemiologic research on rare and understudied cancers, the National Cancer Institute (NCI), in collaboration with the National Institutes of Health Office of Rare Diseases, hosted a series of three leadership workshops.
2,9,10
Advancing research on rare and understudied cancers within the context of consortia and transdisciplinary science was among the workshops' goals. To provide the foundation for such research, the group recognized the need for enhanced involvement of populationbased cancer registries. With this in mind, our specific objectives were to (1) identify and describe the general occurrence of rare cancers in the U.S. using an accepted, conservative threshold and a well-established cancer classification system; (2) compare demographic and histologic characteristics between rare and common cancer sites; and (3 ) explore the occurrence of additional rare cancers typically overlooked in standard reports, including histologic types within anatomically defined rare cancers and distinct anatomic subsites that are otherwise collapsed within broader sites. This information can provide the basis for establishing collaborations, developing new initiatives, and influencing policy to prioritize funding and facilitate rare cancer research.
METHODS
For analysis, we used the Cancer in North America (CINA) Deluxe 1995-2004 research data file, based on the December 2006 data submission from members of the North American Association of Central Cancer Registries (NAACCR). NAACCR is a professional organization of state, provincial, territorial, regional, and metropolitan cancer registries in the U.S. and Canada (www.naaccr.org). Cancer registries in NAACCR are supported by multiple sources. In the U.S., they participate in NCI's Surveillance, Epidemiology, and End Results (SEER) Program or the Centers for Disease Control and Prevention's National Program of Cancer Registries. Among the objectives of NAACCR are to promote uniform data standards; evaluate data quality; certify registries; and compile, disseminate, and promote the use of population-based central cancer registry data. Each year, NAACCR compiles cancer incidence data from member registries that meet highquality standards into the CINA analytic dataset. 11 We limited analyses to U.S. registries that provided explicit permission for this project. To avoid case duplication, we excluded metropolitan-based registries if corresponding data from the entire state were available. As a result, we were able to analyze high-quality cancer incidence data from 41 population-based cancer registries (39 states, one metropolitan area, and Washington, D.C.) representing 80% of the U.S. population. For one registry, we excluded cancer counts and population denominators from one diagnosis year not meeting the highest certification standards because of unresolved data quality exceptions.
We included only invasive, microscopically confirmed cancers, with the exception of in situ urinary bladder cases, which are categorized with invasive disease. Basal cell and squamous cell cancers of the skin are not reportable and were not included in the analysis, whereas we could include basal and squamous cell histologies at all other anatomic sites. We limited cases and population denominators to adults aged 20 years and older. Anatomy and morphology of tumors were defined by the International Classification of Diseases for Oncology (ICD-O) using the standard version for the time and converted when necessary to the ICD-O Third Revision (ICD-O-3). 12 Unexpected anatomic site/histologic type combinations are only included in the CINA dataset after manual review and confirmation by the submitting registry. The term "cancer" refers to any invasive malignancy, regardless of site or histologic type.
The Institutional Review Boards at NAACCR and the Marshfield Clinic Research Foundation approved this study.
incidence rate ratios (IRRs) through SEER*Stat, including 95% confidence intervals (CIs) based on the method of Fay. 14 We categorized cancers into the broad systems and specific "sites" employed by the SEER Site Recode scheme, which is predominantly anatomically based, but also includes exclusive categories for several histologically defined neoplasms. 15 Accordingly, most of the anatomic site-based rates exclude lymphoma, myeloma, leukemia, mesothelioma, and Kaposi sarcoma, as these are accumulated in their own histologically defined site categories regardless of anatomic location. We based primary histologic stratification on the 56 morphologic groups identified within ICD-O-3. 12 We also examined 32 distinct anatomic locations that are subsumed within broader site categories and so would not typically be identified separately in standard cancer surveillance reports.
We adopted the definition of "rare" from a recent NCI-sponsored cancer epidemiology workshop: an incidence of fewer than 150 per million per year (i.e., 15 per 100,000 per year), roughly corresponding in the U.S. to 40,000 new cases per year or fewer.
2, 16 We also examined two lower thresholds-10 cases and 1 case per million per year-to designate additional degrees of rareness.
RESULTS
The 41 cancer registries recorded more than 9 million cases of incident, invasive adult cancers (4.7 million men and 4.4 million women) between 1995 and 2004. Based on an annual threshold of 150 cases per million, 60 of 71 cancer sites met the broad definition of rare, accounting for 25% of reported malignancies (Table 1) . Only one site, pleura (non-mesothelial), had an incidence rate of fewer than one per million per year. Other cancers with incidence rates less than 10 per million per year accounted for almost half of the rare sites, ranging from 1.27 extranodal Hodgkin lymphomas per million (n1,897) to 9.75 vaginal cancers per million women (n8,058). Using this definition, cervix cancer was the most common of the rare sites, with a mean annual incidence of 131.8 per million women. With this definition, only 11 cancers were considered common, including cancers of the prostate, breast, lung, colon, uterine corpus, urinary bladder, rectum, ovary, kidney, melanoma of the skin, and nodal non-Hodgkin lymphoma.
The rates of most rare malignancies varied by gender, some with a male-to-female IRR of 3:1. Cancers of the oral cavity/pharynx, respiratory, and urinary system sites were considerably less common among women than among men, while peritoneal, gallbladder, and anal cancers were more common among women. Such differences in incidence notwithstanding, the designation of rare was consistent by gender across cancer sites with few exceptions. The most striking difference was for breast cancer, which meets the definition for rare among men but not among women.
In contrast to anatomic site, 14 of the 56 histologic groups occurred with an annual frequency of less than one per million, and the annual incidence of an additional 17 histologic types was less than 10 per million (Table 2) . Only eight histologic categories had rates higher than 150 per million per year, although they accounted for 90% of all cancers. Many histologic types are more likely to be found at rare cancer sites than at common cancer sites, including various types of soft tissue sarcomas and basal cell carcinoma (non-skin).
The overall rare to non-rare IRR was 0.33 (Table 3 ). Rare cancers were proportionally (and absolutely) more common than non-rare cancers among young adults aged 20-29 years. The IRRs of rare relative to common cancers then decreased monotonically through adulthood until age 60 years, when the trend flattened and reversed, especially among women (Figure) . Overall, men were more likely than women to have had a rare cancer diagnosis until age 70, after which the rare/non-rare ratios were fairly similar. Black, American Indian/Alaska Native, Asian/Pacific Islander, and Hispanic people with cancer were proportionally more likely to have been diagnosed with a rare cancer as defined in this study than were their white counterparts. This general relation held true for both genders and nearly all ages, except that black and white males older than 40 years of age had very similar rare/non-rare IRRs.
Examining race-specific incidence rates by cancer site provides detail into this general finding. For example, while the black/white IRR for all cancer sites combined was 1.02 (95% CI 1.018, 1.023), black people were less likely than white people to be diagnosed with eight of the 11 non-rare cancers: rectum/rectosigmoid junction (black/white IRR0. Public Health Reports / January-February 2010 / Volume 125 Incidence rates for distinct anatomic locations that are subsumed within broader rare cancer sites as defined by the standard SEER Site Recode scheme are shown for illustrative purposes in Table 4 . All but one (parotid gland) have reported incidence rates below 10 per million per year, and most have a frequency of less than one case per million per year. Among the subsites that are not single-gender cancers, many demonstrate a higher incidence rate among men. Each anatomically based rare cancer site comprised many histologic subtypes (range per site: 12-43 histologic groups, median  25) (Table 5a ). For most rare cancers, the most frequent histologic type generally accounted for a high proportion of the diagnoses, with other types usually representing less than 1% of the total. In contrast, histologic variability exists for some rare cancer sites (e.g., cancers of the salivary glands and retroperitoneum). Histologic variability was also more likely at cancer sites that are defined broadly, such as "other digestive organs" or "other urinary organs."
By contrast, several of the rare cancers defined histologically were prominent in multiple anatomic locations (Table 5b ). For example, only 17% of extranodal non-Hodgkin lymphomas were diagnosed in the most common anatomic location-the skin-whereas 21 other anatomic sites each accounted for at least 1% of all extranodal non-Hodgkin lymphomas.
DISCUSSION
The historical focus of funded research, and corresponding attention in the medical literature, has been on the most common cancers. 10 The resources to identify and describe rare cancer occurrence; understand their causes; and determine the best approaches for prevention, detection, and treatment have been suboptimal, leaving patients, clinicians, and policy makers with limited information. Unfortunately, the deficit of attention has been even more considerable for very rare cancers. 17 Standard cancer surveillance summaries 15, 18, 19 also typically highlight more common cancers, often combining tumors from less frequent anatomic locations and overlooking many neoplasms defined histologically. In response to the recent interest in coordinating and enhancing epidemiologic research on rare cancers, the data presented in this article quantify the occurrence of rare cancers in the U.S. and describe their demographic, anatomic, and histologic features.
Based on the employed definition for "rare" of fewer For younger people, people of nonwhite race, and people of Hispanic ethnicity, the distribution of diagnosed cancers reflects a disproportionate occurrence at rare sites compared with their older, white, or nonHispanic counterparts. The association with young adults is compatible with the recognition that rare cancers often have a larger genetic component to their etiology than more common cancers.
16, 20 The greater likelihood of rare, understudied tumors occurring among nonwhite racial/ethnic groups creates added challenges to achieving our national goals for reducing health disparities in general, 21 and disparities in cancer mortality specifically. 22 This broad dichotomy of "rare" and "common" does mask site-specific heterogeneity in biology and epidemiology, and is partially an artifact of the cancer site distribution among older, white, and non-Hispanic people, in whom the majority of cancers occur. Nevertheless, the fact that cancer site distributions among younger, Hispanic, and nonwhite people are different and tend toward the less common, less studied cancer sites is a practical concern, regardless of the underlying reason.
Encouragingly, interest in rare cancers among scientists, funding agencies, and policy makers has grown in recent years. The U.S. Rare Diseases Act of 2002 focused attention on the benefits of education and research regarding rare conditions. 1 NCI and Office of Rare Diseases workshops on the epidemiology of rare and understudied cancers have brought together topical and methodologic experts to extend the dissemination of current knowledge, promote collaboration, and discuss research gaps along with novel approaches to enhancing rare cancer research capacity in the U.S. 2,9,10,16 Internationally, progress is evidenced by collaborative groups, such as the InterLymph Consortium 23 and Europe's Rare Cancer Network, 24 and scientific articles encouraging the use of populationbased data to support rare cancer research. 25, 26 Well-established population-based resources, such as NCI's SEER program, have been supporting a growing number of rare cancer analyses 7, [27] [28] [29] and new research efforts. 30 While an assessment of all CINA-based sitespecific publications to date indicates a predominant focus on six common cancer sites, 31 recent studies of rare malignancies within the CINA dataset include analyses of biliary tumors, penile cancers, and leukemia subtypes. [32] [33] [34] Other CINA studies have included investigations into rare aspects of common cancer sites, such as primary extraovarian tumors, 35 inflammatory breast cancer, 36 non-carcinoma breast cancers, 37 and non-cutaneous melanomas. 38 Future epidemiologic research with this national dataset can retain substantial case numbers while enhancing disease homogeneity through subsite or histologic stratification. 39 For example, although squamous cell carcinoma is the most common histology in the cervix, adenocarcinomas accounted for 17% of cervical tumors and more than 17,000 cases. This distinction can be important for monitoring the potential impact of the recently introduced prophylactic vaccine against oncogenic human papillomavirus types 16 and 18, as these two viruses are more predominant in cervical adenocarcinomas. 40 For very rare cancers, proponents are calling for the publication of case series, and even single case reports to combat the lack of information. 8, 17 Such cancers can be challenging to diagnose, have limited treatment options, and can be rapidly fatal.
10,17 Rates lower than one per million per year nevertheless result in hundreds of cases in the CINA file potentially available for further research. For example, while sarcomas comprise less than 1% of laryngeal tumors, published findings from a recent case series of 10 laryngeal sarcoma patients 41 could be augmented by investigation of the 352 cases of laryngeal sarcoma contained thus far in the CINA database. Furthermore, over time the numbers of rare cancers in the database will continue to increase.
The CINA analytic file is available to NAACCR members for research following approval of research proposals by NAACCR. Variables in the analytic file include reporting registry; year of diagnosis; type of reporting source; case demographics, such as age, gender, race, and Hispanic ethnicity; tumor characteristics, including site, morphology, behavior, stage and other extent of disease information, grade, diagnostic confirmation, laterality, and sequence number; and links to area-level census attributes and geocoded great-circle distances from care facilities. Select treatment data are also included. Survival data are not yet available in the dataset, but may be in the future as more registries institute systematic case follow-up procedures. With appropriate permissions, CINA data can also support data collection from patients or medical records, and rapid case ascertainment procedures are being piloted in some registries to facilitate such work.
Limitations
This study had several limitations. Analysis was restricted to adults aged 20 years and older. Thus, this article does not provide a complete picture for some cancers prevalent in both children and young adults, such as germ cell tumors or osteosarcomas. Rare cancers among younger age groups will be the subject of a separate analysis. This analysis overlooked some cancers that can be considered rare from other perspectives, including cancers rare in one gender (e.g., male breast cancer), 42 rare cancer subsites within common sites (e.g., appendiceal tumors), 43 and less common histologies of common cancer sites (e.g., rectal carcinoids). 44 The study employed a fairly high threshold for rareness, and it is recognized that research approaches will necessarily differ for very rare cancers with only dozens or hundreds of new cases per year compared with rare cancers with tens of thousands of new cases per year. The designation of rare in this study was also dependent on the narrowness or broadness of the chosen site and histologic definitions. Optimal categorization for each cancer could be addressed during further topic-specific inquiry, such as the recent work developing lymphoma classifications for epidemiologic research by the InterLymph Consortium 45 or a CINA-based investigation into ovarian tumors. 46 Finally, myeloproliferative disorders have only been reportable to cancer registries since 2001, leading to an artificially low case count relative to other cancer types.
CONCLUSIONS
The epidemiology of rare cancers is a challenging area of study, and tumors that are uncommon in the population are also somewhat scarcely documented in the medical and public health literature. The maturing of a nationally representative dataset provides new opportunities to explore the occurrence and characteristics of rare and very rare cancers that have historically been understudied. The use of surveillance data for case ascertainment with possible linkages back to additional data sources could provide opportunities to explore disease etiology, and could potentially lead to advances in treatment and prognosis. We hope that our descriptive analysis encourages such uses of this robust national cancer data resource.
